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Abstract 
Atherosclerosis-prone apolipoprotein E-deficient (Apoe−/−) mice display poor lipoprotein clearance with subsequent 
accumulation of cholesterol ester-enriched particles in the blood, which promote the development of atherosclerotic 
plaques. Therefore, the Apoe−/− mouse model is well established for the study of human atherosclerosis. The systemic 
proinflammatory status of Apoe−/− mice also makes them good candidates for studying chronic obstructive pulmo-
nary disease, characterized by pulmonary inflammation, airway obstruction, and emphysema, and which shares sev-
eral risk factors with cardiovascular diseases, including smoking. Herein, we review the results from published studies 
using Apoe−/− mice, with a particular focus on work conducted in the context of cigarette smoke inhalation studies. 
The findings from these studies highlight the suitability of this animal model for researching the effects of cigarette 
smoking on atherosclerosis and emphysema.
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Overview
Atherosclerosis is a chronic disease in which systemic 
inflammation underlies the accumulation of plaques in the 
arterial intima. Plaques have a lipid-rich core and a thin 
fibrous cap that may rupture, causing thrombosis of the 
narrowed vessels [1]. If not properly controlled, atheroscle-
rotic plaques can obstruct the arterial lumen, leading to 
cardiovascular diseases (CVDs), such as coronary heart dis-
ease (CHD), heart attack, stroke, or angina. More recently, 
an additional mechanism has been recognized, and it is 
responsible for fatal vascular occlusions predominantly in 
younger and female patients [2]. Indeed, thromboses can 
also arise from superficial erosion sites in vascular walls 
characterized by endothelial cell apoptosis on an underly-
ing lipid-poor but proteoglycan- and glycosaminoglycan-
rich plaque structure. It is important to highlight that statin 
treatment, lifestyle changes and other factors may favor the 
stabilization of the classical lipid-rich plaques [2–4]. Nev-
ertheless, in 2011, CHD was responsible for around one in 
every seven deaths in the United States [5].
The development of CVD is associated with a num-
ber of risk factors, including smoking, physical inactiv-
ity, obesity, high blood pressure, diabetes, dyslipidemia, 
and genetic factors. Therapeutics targeted reducing CVD 
face a difficult pre-clinical hurdle because of a dearth of 
appropriate animal models that can capture the complex-
ity of the human disease, which may take over 50 years to 
result in any clinically apparent event.
The development of animal models for CVD has 
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and allowed researchers to assess not only the etiologic 
effects of diet and environmental factors but also to eval-
uate the effectiveness of potential therapies [6]. The most 
widely used murine models for atherosclerosis are apoli-
poprotein E (Apoe) knockout (Apoe−/−) and low den-
sity lipoprotein (LDL) receptor deficient mice (Ldlr−/−), 
which both develop hypercholesterolemia [7–9]. The 
two models have both advantages and disadvantages 
depending on the goals of study. In fact, on a chow diet, 
Apoe−/− mice show higher plasma total cholesterol level 
compared with Ldlr−/−, and thus, develop severe ather-
osclerotic lesions as soon as a few weeks after birth [8, 
10]. Moreover, the deficiency of the endogenous Apoe 
expression leads to an imbalance of cholesterol loading 
specifically in the macrophages. In turn, this stimulates 
cytokine and protease secretion, and triggers subsequent 
inflammation and extracellular matrix degradation [11]. 
These peculiar side effects related with the deficiency of 
Apoe but not Ldlr, confer to Apoe−/− mice greater adapt-
ability for studying several other diseases associated with 
inflammation and extracellular matrix degradation [12], 
such as Alzheimer’s [13, 14], erectile dysfunction [15], 
diet-induced steatohepatitis [16, 17], and recently also 
chronic obstructive pulmonary disease [18–21]. Other 
less frequently reported mouse models of atherosclero-
sis leverage alternative mechanisms of perturbing lipid 
metabolism. The hyperlipidemic APOE*3-Leiden mice 
express a human APOE isoform [22], and are described 
in greater detail below. In the scavenger receptor B1 
(Scarb1) knockout mice, the atheroprotective HDL-C 
levels are elevated but—(apparently) paradoxically—ath-
erosclerosis is increased [23, 24]. However, it has recently 
been shown that patients with a rare genetic inactiva-
tion of the SCARB1 also develop high levels of HDL-C 
associated with a higher atherosclerosis risk [24]. Double 
knockout mice for Scarb1 and Ldlr show more severe 
atherosclerosis and higher mortality than the single 
knockouts, particularly in combination with high fat diet 
[25]. For these mouse models of atherosclerosis, to the 
best of our knowledge, no smoke exposure studies have 
been reported in the literature.
The Apoe−/− model initiated a new era for CVD 
research. The Apoe−/− mouse was developed in 1992 by 
homologous recombination of embryonic stem cells, and 
it is currently the most widely used pre-clinical model of 
atherosclerosis [9, 26]. Apoe is a ligand for lipoprotein 
receptors involved in lipoprotein recognition and clear-
ance. In particular, Apoe serves as a ligand that mediates 
the uptake of chylomicrons, very low-density lipoprotein 
(VLDL) and their remnants to hepatic receptors (LDL 
receptor and LDL receptor-related protein). Therefore, 
Apoe−/− mice show delayed lipoprotein clearance and 
consequently develop hyper- and dyslipoproteinemia 
[27], severe hypercholesterolemia, and atherosclerotic 
lesions even when on a normal diet. Arterial fat depos-
its are observed as early as 3 months after birth [28, 29]. 
By 8 months of age, the coronary arteries can be almost 
occluded when streptozotocin treatment is applied for 
additional acceleration [30, 31].
In the context of CVD development, the creation of 
genetically engineered mouse models became neces-
sary also because of differences in the lipid homeostasis 
between human and murine organisms. For example, 
plasma cholesterol in wild-type mice on a regular chow 
diet is ~ 80 mg/dl, and it is primarily carried by high den-
sity lipoprotein (HDL) particles; moreover, these mice 
present small amounts of LDL and other atherogenic lipo-
proteins, such as VLDL remnants. This high HDL/LDL 
ratio is maintained even when mice are fed with high fat 
diet, indicating that wild-type mice have a high resistance 
to atherosclerosis development. In contrast, human lipid 
profiles show the majority of cholesterol in LDL particles 
(110 mg/dl) [32]. These characteristics make humans sus-
ceptible to HDL/LDL cholesterol ratio fluctuation, confer-
ring a high risk of atherosclerosis and subsequent CVD. 
However, cholesterol transport and metabolism are suffi-
ciently similar in the two species, suggesting that induced 
disturbances in plasma lipoprotein metabolism through 
gene manipulation would also lead to atherosclerosis in 
mice. Thus, the atherosclerotic lesions in Apoe−/− mice 
resemble human lesions in their sites of predilection and 
progression to the fibroproliferative stage [33, 34].
This review aims to highlight the usefulness of Apoe−/− 
mouse model in the context of inhalation toxicology 
studies addressing questions related to the role of ciga-
rette smoke (CS), cessation, and candidate modified risk 
tobacco products (cMRTPs) [35] in the development of 
atherosclerosis and pulmonary diseases (Fig. 1).
Chronic obstructive pulmonary disease and its 
association with CVD
Chronic obstructive pulmonary disease (COPD) is 
typically considered to be a progressive lung disease, 
although it is increasingly thought to be a generalized 
disorder with a wide range of phenotypes [36]. COPD 
also shares some risk factors with CVD, including ciga-
rette smoking.
Growing evidence suggests that, as in CVD, chronic 
systemic inflammation is an important factor in the 
development of COPD. Smoking causes, among other 
effects, a systemic inflammation, which may explain 
why smokers can develop both diseases, as well as other 
comorbidities such as cancer. Generally, COPD patients 
have an increased risk of developing CVD, even after cor-
recting for risk factors such as smoking, and most COPD 
patients die from CVD or cancer rather than respiratory 
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symptoms [37]. Despite their similarities, these disorders 
are often studied in isolation and the increased risk of 
CVD in COPD patients is often underestimated [36]. As 
interactions between the two diseases are not accounted 
for, the treatment of patients with both COPD and CVD 
is therefore often suboptimal [38].
Most animal models show resistance to the develop-
ment of CS inhalation-related pathologies. This is why 
animal models with functional deficits are used to study 
the effects of CS [39]. The study of multiple disease end-
points in one mouse model would be very advantageous, 
as seen in a study of hyperlipidemic APOE*3-Leiden mice 
[22], which are prone to atherosclerosis [21]. These mice 
were intranasally administered low-dose lipopolysaccha-
ride following the induction of emphysema by porcine 
pancreatic elastase. They exhibited pulmonary inflam-
mation [increased interleukin (IL)-6 concentrations] and 
increased atherosclerotic lesion areas, but the presence of 
emphysema did not appear to accelerate atherosclerosis. 
This suggested that CVD/COPD therapy should aim to 
lower pulmonary and systemic inflammation, rather than 
simply treating emphysema.
Apoe−/− mice are a particularly useful strain to inves-
tigate comorbidities associated with cigarette smoking 
because, together with premature atherosclerosis [10], 
they show impaired alveologenesis [40] and develop 
emphysema [20, 41] (Fig.  2). In Apoe−/− mice fed a 
Western-type diet, severe systemic hypercholesterolemia 
accompanied by the abnormal cholesterol efflux induced 
pulmonary inflammation through a TLR4/inflammatory/
MMP cascade, all of which ultimately result in emphy-
sema development [20]. CS exposure of Apoe−/− mice 
clearly boosted these processes. In fact, CS increases 
oxidative stress, mitochondrial damage, and reduces glu-
tathione levels, which in turn trigger arterial thrombosis 
and modulates the size and composition of neointimal 
lesions and thickening [42–44].
In a recent study by Han and colleagues [21], the plasma 
cholesterol concentrations of Apoe−/− and Ldlr−/− mice 
responded differently to sidestream CS exposure, most 
probably because of the differences in lipoprotein metab-
olism between the two strains [45]. Those findings high-
lighted the valuable knowledge gained from studying two 
smoke-related pathologies in one animal model, but our 
recent literature searches on PubMed did not retrieve 
additional studies investigating CS exposure effects on 
Ldlr-/- mice.
The observed link between peripheral systemic changes 
in lipid metabolism and lung dysfunction seems to be 
a novel and clinically relevant factor in public health. 
As discussed above, it is already well established that 
patients with COPD have increased cardiovascular mor-
bidity and mortality, but recent observations in both 
experimental models and humans have indicated that the 
reverse is also true, with the development of COPD in 
patients with atherosclerosis [46].
Fig. 1 Overview of the pathophysiological events and endpoints in the context of inhalation toxicology studies in Apoe−/− mouse model. BALF 
broncho-alveolar lavage fluid. COPD chronic obstructive pulmonary disease
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Human APOE polymorphism and CS: possible 
association with increased CVD risk
Diseases such as CVD and CHD are the result of physio-
logical system homeostasis imbalance. Genetic (e.g., gene 
expression), environmental factors (e.g., smoking), or 
the interaction thereof may be the leading cause of these 
dangerous imbalances. Functional gene polymorphisms 
account for much of the different responses of human 
beings to environmental changes, increasing (or reduc-
ing) the risk of disease development.
In the context of CVD and APOE genotype, human 
populations show a very low frequency of APOE gene defi-
ciencies. However, APOE is polymorphic in humans and 
plasma LDL cholesterol levels, hence atherosclerosis risks 
are strongly associated with the three common APOE iso-
forms, in the following order: APOE4, APOE3, and APOE2 
[47]. Human APOE is a 299 amino acid protein whose 
isoforms are encoded by three APOE alleles (ε2, ε3, ε4) that 
give rise to six different genotypes (ε2/2, ε2/3, ε2/4 ε3/3, 
ε3/4 and ε4/4) [48]. The association between the three iso-
forms and the plasma cholesterol levels is attributed to the 
different affinity with the LDL receptor [49], secondary to 
the recognition and internalization of the APOE containing 
particles [50–52]. Studies on the ε2 allele showed contrast-
ing results. In fact, it was positively associated to hyper-
triglyceridemia [48], but also longevity [53] and negatively 
associated with myocardial infarction [54, 55]. APOE3 
is the most common isoform, and it does not seem to be 
related to increased risk of CVD or other pathologies. On 
the contrary, the ε4 allele has been associated with CHD 
[47], Alzheimer’s disease [56], age-related cognitive decline 
[57], and other diseases [58]. Clinical studies conducted in 
the past 20 years showed not only the role of APOE poly-
morphisms on CVD occurrence, but also the interactions 
with environmental factors such as CS.
CS is associated with increased risk of CHD in men 
with all APOE genotypes, independently from the classi-
cal risk factors, including plasma lipid levels. The modifi-
cation of the CHD risk associated with cigarette smoking 
by APOE polymorphism, was analyzed in the Northwick 
Park Heart Study II (NPHSII) [59], a prospective study of 
CHD in over 3000 UK men. In never-smokers, the CHD 
risk was similar in all APOE genotypes. The presence of 
the ε4 allele confined the CHD risk to current smokers 
alone and was independent of other classical CHD risk 
factors, including plasma lipid levels [60]. Interestingly 
in the ε4 ex-smokers, the risk decreased significantly, 
emphasizing the benefit of smoking cessation. The mech-
anism explaining this correlation could be detected in the 
higher levels of ROS in ε4 subjects [61]. Altogether, these 
studies highlighted the importance of the gene-environ-
ment interaction in the susceptibility to pathologies like 
CVD and CHD and its clear multifactorial nature.
The ability to study comorbidities in the Apoe−/− 
mouse model fulfils the “Reduction” (minimize the 
number of animals used per experiment or study) and 
“Refinement” (minimize the pain, suffering, distress or 
lasting harm that may be experienced by the animals) 
points of the 3R principle in animal research [62, 63]. 
Of note, the reduction and refinement together with the 
“Replacement” principle (aiming in developing methods 
which avoid or replace the use of animals in research), are 
fundamental towards achieving a good match between 
preclinical study outcomes and clinical trials in human 
beings.
Lipoprotein homeostasis in humans and mice
Lipoproteins are a complex and heterogeneous popu-
lation of soluble macromolecular aggregates responsi-
ble for the transport of water-insoluble lipid molecules 
Fig. 2 Lipid imbalance together with endothelial dysfunction and 
systemic inflammation determine the development of atheroscle-
rosis as well as lung inflammation in Apoe−/− mice (and humans). 
CS exposure enhances these processes, thereby increasing oxidative 
stress and inflammation processes
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(mainly triglycerides, cholesterol, fatty acids, and phos-
pholipids) from their site of synthesis (e.g., liver) or 
absorption from food (e.g., gut), to sites of use (e.g., mus-
cle and adipose tissue). There are five types of lipopro-
tein particles (from smallest to largest): HDL, LDL, IDL, 
VLDL (high, low, intermediate, and very low-density 
lipoproteins), and chylomicrons. The lipid cores of these 
lipoprotein particles are coated by phospholipids and 
specific apolipoproteins that play a crucial role in many 
fundamental processes, such as efflux and transport [64], 
enzyme activation [65], and receptor binding [50, 51, 66].
Lipoprotein metabolism pathways differ according to 
the source of contained lipids and show species specific-
ity that is important for preclinical studies.
Exogenous lipoproteins contain dietary fat (triglycer-
ides and cholesterol) that is assembled in chylomicron 
particles [67]. Chylomicrons are released into the lac-
teal vessels, and at the capillaries in peripheral tissue as 
free fatty acids, transforming themselves into APOE-
coated chylomicron remnants (CM). CM particles pen-
etrate the fenestrated endothelium in the liver and will 
subsequently directly interact with ApoE-receptors, like 
the LDL receptor or the LDL receptor related protein 1 
(LRP1) [68, 69]. The involvement of the LDL receptor in 
CM remnant clearance has been investigated showing 
contradictory results. In fact, although it accounts for 
the bulk clearance of serum lipoproteins into the liver, 
including the apoE-containing CM remnants, LDLR defi-
ciency in both patients and animal models does not result 
in a defective clearance of CM remnants, indicating the 
existence of alternative APOE-specific remnant receptors 
for their clearance [70]. The LDL receptor related pro-
teins might significantly contribute to the CM clearance. 
LRP1 belongs to the LRP family that represents a group 
of structurally related transmembrane proteins involved 
in a diverse range of biological activities [71]. The discov-
ery that LRP1 binds APOE led to the notion that it acts 
as a remnant receptor. Consistently, LRP1 deficiency or 
inhibition does result in a decreased clearance of CM 
remnants.It is noteworthy that the metabolism of exog-
enous lipoproteins is preserved across species [72].
Conversely, the endogenous lipoprotein metabolism is 
associated with different key players between humans 
and mice, thus contributing to the missed overlap 
between lipid profiles of the two species under normal 
conditions (Fig.  3). Of note, ApoB is the main apolipo-
protein of LDL, IDL and VLDL, fundamental particles in 
the endogenous lipid transport. Two molecular species of 
ApoB exist: ApoB100 is the full-length molecule that is 
synthesized in the liver, where VLDL particles are assem-
bled for release into the circulation [73]. ApoB48 is pro-
duced by RNA editing from the same gene (APOB), and 
corresponds to the N-terminal fragment of ApoB100, 
therefore lacking the LDLR binding region. In mice this 
latter isoform is expressed in both the liver and in intes-
tine, while in humans, it is only expressed in the intestine 
[74].
At the peripheral tissue capillaries, VLDL particles 
are transformed into IDL [68] after releasing free fatty 
acids. Part of the remaining VLDL particles and/or par-
tially catalyzed VLDL particles bind to VLDL receptors 
expressed in peripheral tissue [75]. In mice, ApoB48-
containing VLDLs and IDLs are internalized by the LRP8 
expressed in the liver. Since the fractional catabolic rate 
for ApoB48-containing lipoproteins is very high com-
pared with that of ApoB100-containing lipoproteins [76], 
VLDL and IDL almost disappear from mouse circulation, 
with the slightest contribution to LDL formation. LDL 
cholesterol thus appears very low in wild-type mice com-
pared with humans (Fig. 3).
The second important difference between human and 
mouse endogenous lipoprotein distribution pertains to 
the HDL cholesterol that, contrarily to LDL, is very high 
in mice and low in humans. This difference is mainly due 
to the absence of the cholesterol ester transfer protein 
(CETP) in mouse plasma compared with the human one 
[77]. Thus, during the reverse cholesterol transport from 
peripheral tissue to the liver, HDL particles receive free 
cholesterol from macrophages through scavenger recep-
tor type B-I (SR-BI) and ATP-binding Cassette proteins 
(ABCs), such as ABCA1 [78]. In humans, after lecithin: 
cholesterol acyltransferase (LCAT)-mediated esterifica-
tion, the esterified cholesterol in HDL particles is trans-
ferred to VLDL, IDL, and LDL thanks to the CETP [79]. 
The absence of this enzyme in mice prevents the cho-
lesterol depletion of HDLs that therefore, represent the 
major lipid-containing particle in the mouse plasma.
Apoe−/− model, CS, and atherosclerosis: an 
overview
Apoe−/− mice have been used to study the effects of 
diverse risk factors on the development of atheroscle-
rosis (Table  1). A long-term (12-month) study assessed 
the impact of mainstream smoke and a high-fat diet 
both separately and in combination [27]. It revealed that 
mainstream smoke significantly increased atherosclerotic 
plaque size in the brachiocephalic artery, while both risk 
factors combined increased the number of elastin-rich 
layers of the plaques, thus accelerating atherosclerosis.
Another study used an Apoe−/− mouse model rather 
than larger animal models to provide more defined 
genetic background, greater statistical power in asso-
ciation with larger sample numbers, and more accurate 
lesion measurements [80]. The results showed that expo-
sure to sidestream CS increased the size of atheroscle-
rotic lesions, particularly in the thoracic region, and thus, 
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the severity of atherosclerosis. This model was later used 
to test the effectiveness of dietary coenzyme Q, a lipid 
antioxidant, for preventing sidestream CS-induced for-
mation of atherosclerotic plaques. Although coenzyme Q 
reduced the growth of spontaneous lesions, it did not sig-
nificantly reduce the growth of smoke-induced plaques 
[81].
Atherosclerosis in the abdominal aorta can lead to the 
development of abdominal aortic aneurysms, which are 
reported to be about nine times more common in smok-
ers than in non-smokers [82]. This process was inves-
tigated in an Apoe−/− mouse model with angiotensin 
II-induced hypertension, which developed aneurysms 
in association with enhanced matrix metalloproteinase 
(MMP) gene expression [83]. Exposure to CS fur-
ther upregulated MMP expression in the abdominal 
aorta, and exacerbated the development and severity of 
aneurysms.
To investigate the effects of CS exposure on plaque 
thrombogenicity, Apoe−/− mice fed a high cholesterol 
diet were exposed to CS for 8  weeks (5  days/week). 
Following atherosclerotic plaque disruption, the tis-
sue factor (TF) formed a complex with factors VII 
and VIIa during thrombin formation. Mice exposed 
to CS showed significantly greater TF immunoreac-
tive areas than those exposed to filtered air, consistent 
with the TF immunoreactivity seen in human carotid 
plaques, albeit at lower levels [84]. Treatment with 
Fig. 3 Lipoprotein structure and abundance in humans, wild type, and Apoe−/− mice plasma. a The general structure of a lipoprotein includes a 
hydrophobic central core consisting of triglycerides, fatty acids, and esterified cholesterol, and a surface monolayer of phospholipid, free cholesterol, 
and specific apolipoproteins. b Schematic representation of cholesterol and triglycerides (TG) abundance in the different plasma lipoprotein species 
among humans, wild type, and Apoe−/− mice
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aspirin, an inhibitor of lipopolysaccharide-induced TF 
expression, attenuated the observed changes in TF in 
Apoe−/− mice, which again paralleled the reduction in 
TF immunoreactive areas seen in smokers undergoing 
carotid endarterectomy who were treated with aspirin 
prior to surgery.
Table 1 Functional endpoint categories related to atherogenesis in studies conducted in Apoe−/− mice
Functional categories related to plaque development were created according to the specific endpoint investigated. This approach facilitated the analysis of dissimilar 
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Thrombin formation activates the clotting cascade and 
platelet activity. Exposure to CS significantly increased 
platelet–fibrinogen binding in Apoe−/− mice, leading to 
significantly greater thrombotic occlusion in these mice 
than in Apoe−/− mice exposed to filtered air [85]. These 
changes were partially reversed by treatment with the 
Purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) 
antagonist, cangrelor. Another P2Y12 antagonist, clopi-
dogrel, also had positive clinical effects in human smok-
ers [86], supporting the applicability of this mouse model 
to human studies.
The development of atherosclerosis involves a num-
ber of inflammatory and vascular remodeling events. 
The enzyme cyclooxygenase-2 (COX-2) is involved in 
prostaglandin biosynthesis and is overexpressed in ath-
erosclerotic lesions. It can be activated by β-catenin, 
a component of cell–cell interactions. Apoe−/− mice 
exposed to CS have been found to increase serum con-
centrations of the inflammatory cytokine interleukin-1, 
and enhanced translocation of β-catenin to the nucleus, 
leading to upregulation of COX-2 and inflammatory 
genes [87]. These cellular changes were proposed to 
underlie the proatherogenic effects in vascular tissue, 
while CS also disrupted the VE-cadherin–β-catenin com-
plexes, induced phosphorylation events and increased 
vascular permeability [88].
The effects of CS exposure on immune suppression 
and subsequent atherosclerosis development were also 
examined in Apoe−/− mice [89]. This study showed 
that intimal thickening induced by carotid arterial cuff-
ing was greater in mice exposed to CS compared with 
mice exposed to filtered air. These effects of CS were 
associated with reduced anti-malondialdehyde oxidized 
LDL IgG titers. This immune modulation is thought to 
increase thickening of the vessel wall.
Some of the atherogenic effects of CS are mediated via 
oxidative stress. Systemic oxidative stress is increased in 
human smokers. This effect was modeled in a study using 
Apoe−/− mice that reported significantly increased serum 
oxidative stress markers, including thiobarbituric acid-
reactive substances, and oxidatively modified low-density 
lipoproteins. The serum and aortic 3-nitrotyrosine con-
centrations were also increased by exposure to CS, and 
these changes were alleviated by treatment with the anti-
oxidant vitamin E [90].
The activity of mitochondrial superoxide dismutase 
2 (SOD2) is reduced in mice exposed to CS. Notably, 
Apoe−/−Sod2+/− mice displayed significant increases in 
atherosclerotic lesion formation compared with control 
Apoe−/− littermates [91]. Thus, increased mitochondrial 
oxidant production, which could be influenced by mito-
chondrial and nuclear genetic variation in humans, may 
directly enhance atherogenic susceptibility.
Apoe−/− mouse models are also appropriate to inves-
tigate the atherosclerotic effects of other pollutants such 
as combustion emissions and ambient air fine particulate 
matter [92–94], which induce inflammatory responses 
and generate reactive oxygen species. Thus, as previously 
described [94], Apoe−/− mice have been used in a diverse 
range of inhalation toxicology studies. These studies have 
assessed exposure to motor vehicle emissions, environ-
mental air particles, and mainstream and sidestream CS, 
with or without the effects of a high-fat diet. The deliv-
ery methods and exposure times varied between studies. 
The pathophysiological events, including inflammation, 
thrombosis, CVD, oxidative stress, and atherogenesis 
(Table  1), and endpoints such as plaque development, 
protein marker expression, and systems toxicology 
assessments, also varied among the studies.
Apoe−/− mouse model to investigate toxicological 
mechanisms of CS, smoking cessation, and harm 
reduction approaches
CS is a complex aerosol mixture, for which more than 
8000 identified smoke constituents have been reported 
[95]. Although it is not clear which particular CS constit-
uents plays which role in any specific disease pathways, 
there is a general consensus on the main classes of chem-
icals from the combustion of tobacco that are harmful 
and potentially harmful [35, 96].
In the recent years, there has been a growing inter-
est in harm reduction approaches to address the health 
risks of smoking [97–100]. Smoking cessation remains 
the most effective approach to minimizing the risk for 
smoking-related diseases [101–103]. However, only a 
small percentage of individuals manage to achieve long-
term abstinence without support [104]. Although nico-
tine replacement therapies (NRT) (e.g., patches, gums, 
and nasal sprays) are often used as smoking cessation 
aids, they do not address the sensory and behavioral 
aspects of the smoking ritual, thus limiting their efficacy 
[105]. Therefore, there is a space for tobacco harm reduc-
tion approaches, which includes the development of less 
harmful products as alternatives to smoking cigarettes. 
These products are designed to deliver nicotine, sensory 
and behavioral aspects that smokers find satisfying while 
significantly reducing or eliminating the harmful and 
potentially harmful chemicals in CS and may be referred 
to as modified risk tobacco products (MRTPs). MRTPs 
were defined by the US Family Smoking Prevention and 
Tobacco Control Act of 2009 as “any tobacco product that 
is sold or distributed for use to reduce harm or the risk of 
tobacco related disease associated with commercially 
marketed tobacco products” [35]. Importantly, accord-
ing with the US Food and Drug Administration pub-
lished draft guidance on “modified risk tobacco product 
Page 9 of 16Lo Sasso et al. J Transl Med  (2016) 14:146 
applications” [35], applications must provide scientific 
evidence to demonstrate that the product will “signifi-
cantly reduce harm and the risk of tobacco-related dis-
eases to individual tobacco users, and benefit the health of 
the population as a whole, taking into account both users 
of tobacco products and persons who do not currently use 
tobacco products.”
Combustion of tobacco results in both pyrolysis and 
pyrosynthesis of many harmful or potentially harmful 
constituents (HPHCs) [106–108]. As the health risk asso-
ciated with CS is due to the HPHCs it contains, the main 
driver for risk reduction is the reduction in exposure to 
HPHCs. Therefore, preventing combustion can produce, 
as compared with CS, a simpler aerosol with a strongly 
reduced content of these toxicants [19, 109, 110]. This 
principle underlies products based on the “heat-not-
burn” principle, in which tobacco is electrically heated in 
a controlled fashion to release nicotine and flavors.
In this context, non-clinical studies in Apoe−/− mice 
are an invaluable preclinical tool for the evaluation of 
candidate MRTPs (cMRTPs), as the effect of such prod-
ucts can be compared with well characterized CS effects 
in the Apoe−/− mouse model (see Table 2).
Using a systems toxicology approach [111, 112], we 
were able to show that CS activates several response 
pathways in both respiratory (lung and nasal) and 
non-respiratory (liver, heart, and aorta) tissues. These 
responses, including inflammation, cell proliferation, 
lipid accumulation, complement, and tissue remodeling, 
were deactivated or strongly attenuated in Apoe−/− mice 
upon smoking cessation, as well as upon the exposure to 
aerosol from a cMRTP [18, 19, 113–115].
Among these studies, particular interest was brought to 
the investigation of lipidomic profiles in different tissues 
(plasma, aorta, liver, and lungs) of Apoe−/− mice exposed 
to CS. CS increased the levels of multiple lipids, including 
ceramides, cholesteryl esters, and phosphatidylcholine 
species, and increased the development of atheroscle-
rotic plaques [27, 103]. One study conducted in 2012 
confirmed these observations [18, 116, 117]. The study 
results showed the effects exerted by both CS (3-month 
exposure) and cessation (3-month CS + 3 months fresh 
air) on Apoe−/− mice plasma and vascular tissue lipi-
domic profile. The CS-dependent increase of plasma 
and aortic lipid levels was reversed following smok-
ing cessation, with a consequent decrease of most lipid 
concentrations, including total cholesterol, VLDL, phos-
phatidylcholine, and sphingomyelin [116, 117]. More 
recently, by using a systems toxicology approach, expo-
sure effects were investigated using the classical toxi-
cological endpoints related to both atherosclerosis and 
respiratory diseases, such as physiology and histology, 
combined with in depth molecular characterization of 
the transcriptome, proteome and lipidome [19, 94].
This study, together with others developed as part of 
a more comprehensive systems toxicology assessment 
framework [112–115], confirmed previous observa-
tions showing a CS-dependent increase of atherogenic 
lipid composition of plasma and vascular tissue. Phil-
lips and colleagues used a different timing for the anal-
ysis, exposing mice up to 8  months [19]. The cessation 
group was defined as the group receiving 2  months of 
CS and 6 months of fresh air. The recovery in the cessa-
tion group in this particular condition was much more 
pronounced than in the previous study with a 3-month 
CS exposure plus 3-month cessation period [117]. This 
is consistent with the assumption that shorter exposure 
periods combined with longer post-exposure periods are 
more efficient at restoring lipids back to less atherogenic 
levels.
The effects of CS exposure and smoking cessation were 
also determined on hepatic lipid, transcriptomic, and 
proteomic profiles in Apoe−/− mice [114, 116, 118]. De 
Leon and colleagues [118] showed that the concentrations 
of many lipids, including free cholesterol, ceramides, and 
sphingomyelin, decreased in the liver of Apoe−/− mice 
following smoking cessation, although the triacylglycerol 
concentration increased. Hepatic triacylglycerol accumu-
lation is indicative of fatty liver disease, but the observed 
increase did not appear to reflect decreased hepatic 
lipolysis or decreased pancreatic lipase. Gene set enrich-
ment analysis of the transcriptomes revealed that fewer 
genes were differentially regulated in the smoking cessa-
tion group than in the CS exposed group. Genes showing 
differential expression included those involved in the cell 
cycle, cholesterol biosynthesis, and platelet activation. A 
more recent study partially confirmed these results [114]. 
In fact, analysis of the liver proteome and transcrip-
tome showed upregulation of several enzymes involved 
in fatty acid and cholesterol metabolism upon CS inha-
lation. It should also be noted that the Apoe deficiency 
per se already causes a skewed hepatic lipid metabolism 
and a higher baseline of hepatic triglyceride accumula-
tion compared with wild-type mice [119, 120]. Therefore, 
while signs of overt hepatotoxicity were absent, livers of 
Apoe−/− mice exposed to CS did exhibit an exacerbated 
dysregulation of fundamental hepatic processes such as 
lipid, xenobiotic and iron homeostasis compared with 
the sham (fresh air exposed) group. These data suggested 
that smoking alone cannot be regarded as a causative 
agent for liver diseases but, rather, as an accelerator in the 
presence of synergistic factors (alcohol, chronic liver dis-
eases) [121–123]. Finally, these changes were significantly 
reduced or absent when mice were exposed continuously 
Page 10 of 16Lo Sasso et al. J Transl Med  (2016) 14:146 
Table 2 Summary of studies using Apoe−/− mice conducted by PMI
Disease, mechanism References Biological matrix Endpoint Effect of CS exposure Effect of cessation
CVD [116] Aorta Lipidomics ↑↗ ND
CVD [117] Aorta Lipidomics ↑ ↓→
CVD [19] Aorta Lipidomics ↑ ↓→
CVD [42] Carotid artery Thrombosis ↑ ND
CVD [42] Carotid artery Endothelial injury ↑ ND
CVD [116] Liver Lipidomics ↑→ ND
CVD [118] Liver Lipidomics ↑↗ ↓↑
CVD [114] Liver Lipidomics ↑↗ ↓↘
CVD [118] Liver Transcriptomics →↗ →
CVD [114] Liver Transcriptomics ↑↗ ↓↘
CVD [114] Liver Proteomics ↑↗ ↓↘
CVD [116] Plasma Lipidomics ↑↗ ND
CVD [117] Plasma Lipidomics ↑→ ↓→
CVD [19] Plasma Lipidomics ↑↗ ↓↘
COPD [113] Lung Lipidomics ↑↗ ↓↘
COPD [113] Lung Transcriptomics ↑↗ ↓↘
COPD [113] Lung Proteomics ↑↗ ↓↘
Atherosclerosis [116] Aorta Plaque size ↑ ND
Atherosclerosis [117] Aorta Plaque size ↑↘ ↘
Atherosclerosis [19] Aorta Plaque size ↑ →
Atherosclerosis [118] Aorta Plaque size ↑ ND
Atherosclerosis [29] Aorta Plaque size ↑ ND
Atherosclerosis [27] BA Plaque size ↑→ ND
Atherosclerosis [27] Aortic arch Plaque size ↑→ ND
Exposure markers [18] Blood COHb ↑ ↓
Exposure markers [18] Urine Nicotine metabolites ↑ ↓
Exposure marker [117] Blood COHb ↑ ↓
Exposure marker [118] Blood COHb ↑ ↓
Exposure marker [117] Urine Nicotine metabolites ↑ ↓
Exposure markers [19] Blood COHb ↑ ↓
Exposure markers [19] Urine Nicotine metabolites ↑ ↓
Inflammation [18] Lung BALF ↑ ↓↘
Inflammation [18] NRE Histopathology ↑ ↓
Inflammation [18] Lung Transcriptomics ↑↓ ↓↑
Inflammation [116] Liver Transcriptomics ↑↗ ND
Inflammation [124] Lung BALF ↑→ ↓
Inflammation [29] Aorta Transcriptomics ↑ ND
Inflammation [127] Lung Transcriptomics ↑↓ ND
Inflammation [127] Lung BALF ↑ ND
Inflammation [127] Respiratory Histopathology ↑ ND
Inflammation [127] Respiratory Network model ↑ ND
Inflammation [113] Lung Lipidomics ↑ ↓
Inflammation [19] Urine Inflammatory biomarker ↑ ↓
Inflammation [19] Lung BALF ↑ ↓
Inflammation [19] NRE Histopathology ↑ ↓
Inflammation [19] Lung Histopathology ↑ ↓
COPD—emphysema [18] Lung Lung morphometry ↑ ↘
COPD—emphysema [19] Lung Lung function ↑ ↘
COPD—emphysema [19] Lung Lung morphometry ↑ ↘
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to the cMRTP aerosol, upon cessation regimen or switch-
ing to the cMRTP [114].
Thomson and colleagues [124] developed a means of 
assessing the biological impact of exposure to biological 
and chemical substances based on hypotheses (typically, 
the predicted upstream regulators of the measured dif-
ferentially expressed genes), subnetworks, and networks. 
Transcriptomics data were evaluated by computational 
modeling that combined the data with a priori knowl-
edge from a knowledgebase to determine the effects at 
the molecular and systems levels. This approach has been 
applied to a number of models, including two smok-
ing cessation studies using Apoe−/− mice [18, 19]. Both 
these studies revealed that in respiratory tract tissues, 
genes involved in the cell cycle, pulmonary inflammation, 
senescence, and necroptosis were significantly perturbed 
by CS exposure. This was corroborated by a decrease in 
the perturbation of biological mechanisms related to cell 
proliferation, tissue repair/angiogenesis, cell stress, cell 
fate, and pulmonary inflammation in the smoking ces-
sation group compared with the group under continu-
ous CS exposure. Similarly, the predicted increase in the 
immune cell response subnetworks was supported by a 
significant increase in the immune cell count and their 
secreted inflammatory mediators in bronchoalveolar lav-
age fluid.
Because advanced atherosclerotic lesions are difficult to 
recreate experimentally, little is known about the mecha-
nisms underlying plaque instability and rupture. Instead, 
this was modeled in a vascular inflammatory processes 
network [29], which, like the lung-specific models applied 
for respiratory tract evaluations, used reverse causal rea-
soning [125] to explain and integrate differential gene 
expression data from large datasets. The latter approach 
showed that distinct molecular pathways are involved 
in different stages of atherosclerosis in Apoe−/− mice 
exposed to CS. Thus, the Apoe−/− mouse model shares 
many causal mechanisms with those of advanced athero-
sclerotic lesions in human coronary arteries, including 
endothelial cell activation, endothelial/monocyte interac-
tion, foam cell formation, and plaque destabilization.
Stegemann and colleagues analyzed the lipid compo-
sition of human atherosclerotic plaques from carotid 
endarterectomies and reported a list of plaque-enriched 
lipid species, also with a strong contribution from sterol 
lipids, sphingolipids, and glycerophospholipids [126]. In 
Fig.  4, we present a comparison of the Apoe−/− murine 
aortic arch lipid species (data from [19]) that have these 
human plaque-enriched lipids in common. With the 
exception of two phosphatidylcholines (PCs) and one 
phosphatidylethanolamine (PE), all these common lipids 
were also significantly higher in aortic arches from 
Apoe−/− mice exposed for 8  months to CS compared 
with tissue from the sham-exposed controls. Conversely, 
no significant changes were observed following exposure 
to aerosol from an electrically heated cMRTP, or in mice 
that were switched to the cMRTP or to fresh air (cessa-
tion group) after a 2-month CS exposure. This correla-
tion between human and murine plaque-enriched lipids 
is suggestive of related alterations in lipid metabolism 
in this mouse model of atherosclerosis. Taken together, 
these findings suggest that similar mechanisms are 
common to both species at the early stages of smoking-
related atherosclerosis.
Another study used a systems biology approach 
together with reverse causal reasoning to investigate 
the mechanisms associated with emphysema develop-
ment in five different mouse models, including Apoe−/− 
mice [127]. Emphysema is a component of COPD, but 
it appears to have a strong underlying genetic element 
Table 2 continued
Disease, mechanism References Biological matrix Endpoint Effect of CS exposure Effect of cessation
Inflammation/cell cycle/necroptosis [19] Lung Network model ↑ ↓
Inflammation/cell cycle/necroptosis [19] Lung Transcriptomics ↑ ↓
Inflammation/cell cycle/necroptosis [19] Lung Proteomics ↑ ↓
Inflammation/cell cycle/necroptosis [124] Lung Network model ↑ ↓
Inflammation/cell cycle/necroptosis [124] Lung Transcriptomics ↑ ↓
Oxidative stress [18] Lung BALF ↑ ↓↘
Oxidative stress [18] NRE Transcriptomics ↑↓ ↓↑
Oxidative stress [114] Liver Transcriptomics ↑ ↓
Oxidative stress [114] Liver Proteomics ↑ ↓
Arrows indicate increase (upwards), decrease (downwards), no change (to the right), trend to increase (north east), and trend to decrease (south east). Arrows for the 
cigarette smoke (CS) effect indicate changes compared with unexposed mice, and arrows for the cessation effect indicate differences compared with continued CS 
exposure
COHb carboxyhemoglobin; BALF bronchoalveolar lavage fluid; CVD cardiovascular disease; NRE nasal respiratory epithelium; COPD chronic obstructive pulmonary 
disease; BA brachiocephalic artery; ND not done
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in its development because not all smokers develop this 
disease. Combining large-scale transcriptomics data sets 
from four different studies, 39 biological and chemical 
substances based on hypotheses were identified as poten-
tial mechanisms associated with emphysema induced 
by CS exposure. The transcription nuclear factor κB, 
Th1-associated cytokines (tumor necrosis factor-α, IL-2, 
and interferon-c), IL-17A and IL-17F were predicted 
to increase following CS exposure. These fundamental 
mechanisms are likely to be applicable to human COPD.
Conclusions
To understand disease mechanisms in human, it is some-
times necessary to use animal models that can be char-
acterized in depth. Oftentimes, models are used to study 
one particular condition. It is possible, however, to bring 
the model closer to the human situation by studying 
multiple comorbidities at once, as it is discussed in this 
review for the Apoe−/− mouse. Although atherogenesis 
is accelerated in Apoe−/− mice compared with humans, 
this rodent model is useful for assessing the mechanisms 
underlying the progression of atherosclerosis that are 
also relevant to humans owing to the similarities in the 
underlying mechanisms. In this review article we discuss 
scientific publications that overall demonstrated that the 
Apoe−/− mouse model is a suitable and relevant tool for 
examining the effects of CS, smoking cessation, or any 
product aimed at reducing the risk associated with CS, 
not only on atherosclerosis but also on lung inflamma-
tion and emphysema. In this context, the versatility of the 
Apoe−/− mouse model is highlighted by the possibility 
not only to allow analysis in terms of genetic, molecular, 
and physiological mechanisms in cardiovascular systems, 
but also to apply a similar “systems” approach to other 
respiratory and non-respiratory tissues. Thus, the use of 
the Apoe−/− mouse model appears very appropriate in 
the framework of inhalation toxicology studies.
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